{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:15:58Z","timestamp":1788916558237,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013003","name":"Universit\u00e0 degli Studi di Cagliari","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Thyroid alterations including de novo appearance of thyroid autoimmunity are adverse effects of tyrosine kinase inhibitors, used in solid and hematologic cancer therapy, but the relationship between thyroid alterations during this treatment and the outcome of chronic myeloid leukemia remains unclear. Aim of this study was to investigate whether the presence of thyroid alterations may affect the clinical outcome of chronic myeloid leukemia on tyrosine kinase inhibitors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We evaluated thyroid function and autoimmunity in 69 chronic myeloid leukemia patients on long-term therapy looking at the association between thyroid abnormalities and disease molecular response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 24 of 69 (34.8%) had one or more thyroid abnormalities during therapy. A high percentage of patients (21\/69, 30.4%) showed thyroid autoimmunity (positive thyroid autoantibodies with ultrasound hypoechogenicity), while clinical and subclinical hypothyroidism and subclinical hyperthyroidism were, respectively, found in 4 of 69 (5.8%) and 3 of 69 (4.3%) of cases. Second-generation tyrosine kinase inhibitors resulted significantly associated (14\/32, 43.7%) with Hashimoto\u2019s thyroiditis, compared to first generation (7\/37, 18.9%; <jats:italic>p<\/jats:italic>\u2009=\u20090.03). Interestingly, we also found a significant association between euthyroid (14\/26, 53.8%) and hypothyroid Hashimoto\u2019s thyroiditis (4\/26, 15.4%) in patients with deep molecular response, as compared to euthyroid (3\/43, 7%; <jats:italic>p<\/jats:italic>\u2009=\u20090.0001) and hypothyroid (0\/43, 0%; <jats:italic>p<\/jats:italic>\u2009=\u20090.02) Hashimoto\u2019s thyroiditis patients with major molecular response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study confirms and extends our knowledge on the tyrosine kinase inhibitors effects on thyroid, showing that thyroid autoimmunity is frequently observed in chronic myeloid leukemia patients on long-term therapy and is associated with a better oncological response.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-021-01613-5","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T13:03:16Z","timestamp":1626786196000},"page":"291-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors"],"prefix":"10.1007","volume":"45","author":[{"given":"R.","family":"Rodia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"La Nasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"Simula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Velluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Loviselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9924-5192","authenticated-orcid":false,"given":"F.","family":"Boi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"1613_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/725410","volume":"2013","author":"H Ahmadieh","year":"2013","unstructured":"Ahmadieh H, Salti I (2013) Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment. Biomed Res Int 2013:725410. https:\/\/doi.org\/10.1155\/2013\/725410","journal-title":"Biomed Res Int"},{"issue":"12","key":"1613_CR2","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.leukres.2014.09.016","volume":"38","author":"M Breccia","year":"2014","unstructured":"Breccia M, Molica M, Alimena G (2014) How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review. Leuk Res 38(12):1392\u20131398. https:\/\/doi.org\/10.1016\/j.leukres.2014.09.016","journal-title":"Leuk Res"},{"issue":"11","key":"1613_CR3","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/leu.2008.106","volume":"22","author":"G Caocci","year":"2008","unstructured":"Caocci G, Atzeni S, Orr\u00f9 N, Azzena L, Martorana L, Littera R, Ledda A, La Nasa G (2008) Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Leukemia 22(11):2127\u20132128. https:\/\/doi.org\/10.1038\/leu.2008.106","journal-title":"Leukemia"},{"issue":"3","key":"1613_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/thy.2010.1620","volume":"20","author":"JM Hershman","year":"2010","unstructured":"Hershman JM, Liwanpo L (2010) How does sunitinib cause hypothyroidism? Thyroid 20(3):243\u2013244. https:\/\/doi.org\/10.1089\/thy.2010.1620","journal-title":"Thyroid"},{"issue":"3","key":"1613_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/EJE-08-0648","volume":"160","author":"F Illouz","year":"2009","unstructured":"Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P (2009) Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 160(3):331\u2013336. https:\/\/doi.org\/10.1530\/EJE-08-0648","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1613_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","volume":"6","author":"F Torino","year":"2009","unstructured":"Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G (2009) Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6(4):219\u2013228. https:\/\/doi.org\/10.1038\/nrclinonc.2009.4","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1613_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1089\/thy.2017.0579","volume":"28","author":"MG Lechner","year":"2018","unstructured":"Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE (2018) Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced nonthyroidal cancer patients. Thyroid 28(4):437\u2013444. https:\/\/doi.org\/10.1089\/thy.2017.0579","journal-title":"Thyroid"},{"issue":"11","key":"1613_CR8","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1089\/thy.2010.0251","volume":"20","author":"TD Kim","year":"2010","unstructured":"Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Pl\u00f6ckinger U, Braun D, Schweizer U, Arnold R, D\u00f6rken B et al (2010) Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 20(11):1209\u20131214. https:\/\/doi.org\/10.1089\/thy.2010.0251","journal-title":"Thyroid"},{"issue":"3","key":"1613_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/thy.2009.0125","volume":"20","author":"A Rogiers","year":"2010","unstructured":"Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Sch\u00f6ffski P (2010) Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 20(3):317\u2013322. https:\/\/doi.org\/10.1089\/thy.2009.0125","journal-title":"Thyroid"},{"key":"1613_CR10","doi-asserted-by":"publisher","unstructured":"Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, et al. (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 7;145(9):660\u20134. https:\/\/doi.org\/10.7326\/0003-4819-145-9-200611070-00008","DOI":"10.7326\/0003-4819-145-9-200611070-00008"},{"issue":"11","key":"1613_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1089\/thy.2007.0104","volume":"17","author":"JE Faris","year":"2007","unstructured":"Faris JE, Moore AF, Daniels GH (2007) Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 17(11):1147\u20131149. https:\/\/doi.org\/10.1089\/thy.2007.0104","journal-title":"Thyroid"},{"issue":"4","key":"1613_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1365-2265.2008.03253.x","volume":"69","author":"M Grossmann","year":"2008","unstructured":"Grossmann M, Premaratne E, Desai J, Davis ID (2008) Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69(4):669\u2013672. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03253.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1613_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/thy.2006.0308","volume":"17","author":"E Wong","year":"2007","unstructured":"Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17(4):351\u2013355. https:\/\/doi.org\/10.1089\/thy.2006.0308","journal-title":"Thyroid"},{"issue":"9","key":"1613_CR14","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1210\/jc.2007-0586","volume":"92","author":"D Mannavola","year":"2007","unstructured":"Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L (2007) A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92(9):3531\u20133534. https:\/\/doi.org\/10.1210\/jc.2007-0586","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1613_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","volume":"78","author":"JW De Groot","year":"2005","unstructured":"De Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP (2005) Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78(4):433\u2013438. https:\/\/doi.org\/10.1016\/j.clpt.2005.06.010","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1613_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1089\/thy.2009.0414","volume":"20","author":"N Makita","year":"2010","unstructured":"Makita N, Miyakawa M, Fujita T, Iiri T (2010) Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 20(3):323\u2013326. https:\/\/doi.org\/10.1089\/thy.2009.0414","journal-title":"Thyroid"},{"issue":"11","key":"1613_CR17","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1089\/thy.2015.0170","volume":"25","author":"F Pani","year":"2015","unstructured":"Pani F, Atzori F, Baghino G, Boi F, Tanca L, Ionta MT, Mariotti S (2015) Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved? Thyroid 25(11):1255\u20131261. https:\/\/doi.org\/10.1089\/thy.2015.0170","journal-title":"Thyroid"},{"issue":"4","key":"1613_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1089\/thy.2017.0587","volume":"28","author":"MG Lechner","year":"2018","unstructured":"Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE (2018) Hypothyroidism during tyrosine kinase inhibitor therapy is associated with longer survival in patients with advanced nonthyroidal cancers. Thyroid 28(4):445\u2013453. https:\/\/doi.org\/10.1089\/thy.2017.0587","journal-title":"Thyroid"},{"key":"1613_CR19","doi-asserted-by":"publisher","unstructured":"Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 15;112(13):4808\u201317. https:\/\/doi.org\/10.1182\/blood-2008-07-077958","DOI":"10.1182\/blood-2008-07-077958"},{"issue":"12","key":"1613_CR20","doi-asserted-by":"publisher","first-page":"E332","DOI":"10.1002\/ajh.25997","volume":"95","author":"S Patel","year":"2020","unstructured":"Patel S, Nayernama A, Jones SC, de Claro RA, Waldron PE (2020) BCR-ABL1 tyrosine kinase inhibitor-associated thyroid dysfunction: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature. Am J Hematol 95(12):E332\u2013E335. https:\/\/doi.org\/10.1002\/ajh.25997","journal-title":"Am J Hematol"},{"issue":"4","key":"1613_CR21","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"issue":"3","key":"1613_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/jcu.20008","volume":"32","author":"M Loy","year":"2004","unstructured":"Loy M, Cianchetti ME, Cardia F, Melis A, Boi F, Mariotti S (2004) Correlation of computerized gray-scale sonographic findings with thyroid function and thyroid autoimmune activity in patients with Hashimoto\u2019s thyroiditis. J Clin Ultrasound 32(3):136\u2013140. https:\/\/doi.org\/10.1002\/jcu.20008","journal-title":"J Clin Ultrasound"},{"issue":"3","key":"1613_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/thy.2000.10.251","volume":"10","author":"OM Pedersen","year":"2000","unstructured":"Pedersen OM, Aardal NP, Larssen TB, Varhaug JE, Myking O, Vik-Mo H (2000) The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid 10(3):251\u2013259. https:\/\/doi.org\/10.1089\/thy.2000.10.251","journal-title":"Thyroid"},{"issue":"12","key":"1613_CR24","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1089\/thy.2007.0014","volume":"17","author":"Y Ito","year":"2007","unstructured":"Ito Y, Amino N, Yokozawa T, Ota H, Ohshita M, Murata N, Morita S, Kobayashi K, Miyauchi A (2007) Ultrasonographic evaluation of thyroid nodules in 900 patients: comparison among ultrasonographic, cytological, and histological findings. Thyroid 17(12):1269\u20131276. https:\/\/doi.org\/10.1089\/thy.2007.0014","journal-title":"Thyroid"},{"issue":"4","key":"1613_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40618-017-0757-0","volume":"41","author":"F Boi","year":"2018","unstructured":"Boi F, Pani F, Cal\u00f2 PG, Lai ML, Mariotti S (2018) High prevalence of papillary thyroid carcinoma in nodular Hashimoto\u2019s thyroiditis at the first diagnosis and during the follow-up. J Endocrinol Invest 41(4):395\u2013402. https:\/\/doi.org\/10.1007\/s40618-017-0757-0","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"1613_CR26","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jama.1990.03440110095035","volume":"263","author":"MI Surks","year":"1990","unstructured":"Surks MI, Chopra IJ, Mariash CN, Nicoloff JT, Solomon DH (1990) American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA 263(11):1529\u20131532","journal-title":"JAMA"},{"issue":"2","key":"1613_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jama.291.2.228","volume":"291","author":"MI Surks","year":"2004","unstructured":"Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA et al (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291(2):228\u2013238. https:\/\/doi.org\/10.1001\/jama.291.2.228","journal-title":"JAMA"},{"issue":"12","key":"1613_CR28","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","volume":"4","author":"C Vener","year":"2020","unstructured":"Vener C, Banzi R, Ambrogi F, Ferrero A, Saglio G, Pravettoni G, Sant M (2020) First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv 4(12):2723\u20132735. https:\/\/doi.org\/10.1182\/bloodadvances.2019001329","journal-title":"Blood Adv"},{"issue":"6","key":"1613_CR29","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.clml.2016.03.003","volume":"16","author":"S Yun","year":"2016","unstructured":"Yun S, Vincelette ND, Segar JM, Dong Y, Shen Y, Kim DW, Abraham I (2016) Comparative effectiveness of newer tyrosine kinase inhibitors versus imatinib in the first-line treatment of chronic-phase chronic myeloid leukemia across risk groups: a systematic review and meta-analysis of eight randomized trials. Clin Lymphoma Myeloma Leuk 16(6):e85-94. https:\/\/doi.org\/10.1016\/j.clml.2016.03.003","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9\u201310","key":"1613_CR30","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1080\/0284186X.2016.1201214","volume":"55","author":"R Gurion","year":"2016","unstructured":"Gurion R, Raanani P, Vidal L, Leader A, Gafter-Gvili A (2016) First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response\u2014systematic review and meta-analysis. Acta Oncol 55(9\u201310):1077\u20131083. https:\/\/doi.org\/10.1080\/0284186X.2016.1201214","journal-title":"Acta Oncol"},{"issue":"6","key":"1613_CR31","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1530\/eje.1.02158","volume":"154","author":"F Pacini","year":"2006","unstructured":"Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, Taskforce ETC (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154(6):787\u2013803. https:\/\/doi.org\/10.1530\/eje.1.02158","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1613_CR32","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/annonc\/mdl112","volume":"17","author":"JW de Groot","year":"2006","unstructured":"de Groot JW, Links TP, van der Graaf WT (2006) Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol 17(11):1719\u20131720. https:\/\/doi.org\/10.1093\/annonc\/mdl112","journal-title":"Ann Oncol"},{"issue":"9","key":"1613_CR33","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1210\/jc.2007-0649","volume":"92","author":"JW de Groot","year":"2007","unstructured":"de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE (2007) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92(9):3466\u20133469. https:\/\/doi.org\/10.1210\/jc.2007-0649","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1613_CR34","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1530\/EJE-08-0006","volume":"158","author":"JM Dora","year":"2008","unstructured":"Dora JM, Leie MA, Netto B, Fogliatto LM, Silla L, Torres F, Maia AL (2008) Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. Eur J Endocrinol 158(5):771\u2013772. https:\/\/doi.org\/10.1530\/EJE-08-0006","journal-title":"Eur J Endocrinol"},{"key":"1613_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/736092","volume":"2015","author":"S Bakerywala","year":"2015","unstructured":"Bakerywala S, Schwarcz MD, Goldberg MD, Valiquette G, Weiss IA (2015) Nilotinib-associated destructive thyroiditis. Case Rep Endocrinol 2015:736092. https:\/\/doi.org\/10.1155\/2015\/736092","journal-title":"Case Rep Endocrinol"},{"issue":"1","key":"1613_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1530\/EJE-14-0182","volume":"171","author":"AP Delitala","year":"2014","unstructured":"Delitala AP, Pilia MG, Ferreli L, Loi F, Curreli N, Balaci L, Schlessinger D, Cucca F (2014) Prevalence of unknown thyroid disorders in a Sardinian cohort. Eur J Endocrinol 171(1):143\u2013149. https:\/\/doi.org\/10.1530\/EJE-14-0182","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1613_CR37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12020-012-9703-2","volume":"42","author":"DS McLeod","year":"2012","unstructured":"McLeod DS, Cooper DS (2012) The incidence and prevalence of thyroid autoimmunity. Endocrine 42(2):252\u2013265. https:\/\/doi.org\/10.1007\/s12020-012-9703-2","journal-title":"Endocrine"},{"issue":"9","key":"1613_CR38","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1089\/105072501316973109","volume":"11","author":"A Loviselli","year":"2001","unstructured":"Loviselli A, Velluzzi F, Mossa P, Cambosu MA, Secci G, Atzeni F, Taberlet A, Balestrieri A, Martino E, Grasso L et al (2001) Sardinian Schoolchildren Study Group. The Sardinian Autoimmunity Study: 3. Studies on circulating antithyroid antibodies in Sardinian schoolchildren: relationship to goiter prevalence and thyroid function. Thyroid 11(9):849\u2013857. https:\/\/doi.org\/10.1089\/105072501316973109","journal-title":"Thyroid"},{"issue":"1","key":"1613_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00592-015-0751-y","volume":"53","author":"F Velluzzi","year":"2016","unstructured":"Velluzzi F, Secci G, Sepe V, Klersy C, Shattock M, Foxon R, Songini M, Mariotti S, Locatelli M, Bottazzo GF et al (2016) Sardinian Autoimmunity Study Group. Prediction of type 1 diabetes in Sardinian schoolchildren using islet cell autoantibodies: 10-year follow-up of the Sardinian schoolchildren type 1 diabetes prediction study. Acta Diabetol 53(1):73\u201379. https:\/\/doi.org\/10.1007\/s00592-015-0751-y","journal-title":"Acta Diabetol"},{"issue":"1","key":"1613_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40345-017-0114-4","volume":"6","author":"A Bocchetta","year":"2018","unstructured":"Bocchetta A, Ambrosiani L, Baggiani G, Pisanu C, Chillotti C, Ardau R, Velluzzi F, Piras D, Loviselli A, Pani A (2018) Circulating antithyroid antibodies contribute to the decrease of glomerular filtration rate in lithium-treated patients: a longitudinal study. Int J Bipolar Disord 6(1):3. https:\/\/doi.org\/10.1186\/s40345-017-0114-4","journal-title":"Int J Bipolar Disord"},{"issue":"5","key":"1613_CR41","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.2337\/diabetes.50.5.1200","volume":"50","author":"F Cucca","year":"2001","unstructured":"Cucca F, Dudbridge F, Loddo M, Mulargia AP, Lampis R, Angius E, De Virgiliis S, Koeleman BP, Bain SC, Barnett AH et al (2001) The HLA-DPB1\u2013associated component of the IDDM1 and its relationship to the major loci HLA-DQB1, -DQA1, and -DRB1. Diabetes 50(5):1200\u20131205. https:\/\/doi.org\/10.2337\/diabetes.50.5.1200","journal-title":"Diabetes"},{"issue":"23","key":"1613_CR42","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1093\/hmg\/ddh319","volume":"13","author":"MG Marrosu","year":"2004","unstructured":"Marrosu MG, Motzo C, Murru R, Lampis R, Costa G, Zavattari P, Contu D, Fadda E, Cocco E, Cucca F (2004) The co-inheritance of type 1 diabetes and multiple sclerosis in Sardinia cannot be explained by genotype variation in the HLA region alone. Hum Mol Genet 13(23):2919\u20132924. https:\/\/doi.org\/10.1093\/hmg\/ddh319","journal-title":"Hum Mol Genet"},{"issue":"8","key":"1613_CR43","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/BF03349681","volume":"17","author":"E Martino","year":"1994","unstructured":"Martino E, Loviselli A, Velluzzi F, Murtas ML, Carta M, Lampis M, Murru R, Mastinu A, Arba ML, Sica V et al (1994) Endemic goiter and thyroid function in central-southern Sardinia. Report on an extensive epidemiological survey. J Endocrinol Invest 17(8):653\u2013657. https:\/\/doi.org\/10.1007\/BF03349681","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"1613_CR44","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1089\/thy.2016.0159","volume":"26","author":"F Pani","year":"2016","unstructured":"Pani F, Atzori F, Baghino G, Boi F, Ionta MT, Tanca L, Scartozzi M, Mariotti S (2016) Hypothyroidism and thyroid autoimmunity as a prognostic biomarker of better response in metastatic cancer long-term survivors treated with sunitinib. Thyroid 26(9):1336\u20131337. https:\/\/doi.org\/10.1089\/thy.2016.0159","journal-title":"Thyroid"},{"issue":"12","key":"1613_CR45","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","volume":"53","author":"JL Steegmann","year":"2012","unstructured":"Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G (2012) Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 53(12):2351\u20132361. https:\/\/doi.org\/10.3109\/10428194.2012.695779","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01613-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01613-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01613-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T10:21:15Z","timestamp":1642846875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01613-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1613"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01613-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"16 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of University of Cagliari approved this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Patients signed informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}